Publication | Open Access

Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction

InflammationThrombosisPlasma Ip-10CytokineCardiovascular DiseaseMedicineInterleukin-6 Receptor InhibitionImmune RegulationImmunologyPharmacotherapyImmune FunctionPharmacologyTocilizumab InducesAcute Myocardial InfarctionMyocardial Infarction